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Recent advances in DNA sequencing technology are providing unprecedented opportunities for comprehensive analysis of cancer
genomes, exomes, transcriptomes, as well as epigenomic components. The integration of these data sets with well-annotated
phenotypic and clinical data will expedite improved interventions based on the individual genomics of the patient and the specific
disease.
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The family of diseases that we refer to as cancer represents a field
of application for genomics of truly special importance and
opportunity. It is perhaps the first area in which not only will
genomics continue to make major contributions to the under-
standing of the disease through holistic discovery of causal
genome-wide perturbations but will also be the first field in which
whole-genome analysis is used in clinical applications such as
precise diagnosis, prognosis and prediction of response to
treatment. There are several reasons that underlie the excitement
due to access to whole-genome DNA sequencing. First, the altered
cancer genome is the direct cause of disease and precisely defines
the tumour phenotype. Second, as we have access to both diseased
tissue and normal samples from the same patient, and as most
cancer genomic alterations represent somatic events, we can
discern with confidence those changes specific to cancer. Third, in
cancer, genomic alterations are progressive and in some cancer
cases, changes related to disease stage, development of metastases
and drug resistance are discernible. Thus, the increasing
sophistication of systems biology now means that the complex
interplay of events that activate and inactivate specific genes and
pathways can be deduced directly from deep genomic and
transcriptomic sequencing (Figure 1). In this overview, perspective
is provided with respect to the approaches that have been
developed over the past decade and emerging opportunities for
discovery and eventual application.
Starting in the late 1990s, much of the gene- and transcriptome-
based data were provided through large-scale community resource
projects such as the NCI’s Cancer Genome Anatomy Project, the
Sanger Centre’s Cancer Genome Project and the Human Cancer
Genome Project of the Ludwig Institute for Cancer Research
(Strausberg et al, 2003). These projects complemented the growing
knowledge of specific gene alterations discovered by the cancer
research community and provided a basis for more global views
of tumourigenesis, on the basis of knowledge of gene families and
signal transduction networks. More recently, technological changes
in DNA sequencing, including the recently introduced ‘NextGen’
instruments and associated molecular technologies, have enabled
both higher-throughput and more sensitive assays that provide
important new opportunities for basic discovery and clinical
application (Mardis, 2009). The new technologies also provide for
more democratised large-scale DNA sequencing that will facilitate
enhanced cancer genomics opportunities for the cancer research
community within both tumour biology and clinical laboratories.
Recently, the first genomic sequence of a cancer (a case of acute
myeloid leukaemia (AML)) was described by Ley et al (2008) in a
landmark publication, an important advance in our knowledge of
the complete molecular repertoire of cancers.
TOWARDS AN ERA OF WHOLE-GENOME CANCER
SEQUENCING
In the report by Ley et al, which describes the complete genome
sequencing of AML, Illumina genome analyser (GA) technology
was used to attain a nearly 33-fold coverage of the genome. In
addition, a 14-fold genome coverage of a normal skin sample from
the same patient was obtained. The cancer genome of this
individual is cytogenetically normal and diploid, representing a
far simpler case than the genomes of cytogenetically complex and
much more common carcinomas. Nevertheless, the analysis
provides an informative snapshot of what we can expect from
whole-cancer genome shotgun sequencing. The central focus of
this genome project is the detection of somatic mutations, the
principal driving force in cancer.
Of the somatic mutations detected, more than 11000 were
located within annotated genes. However, most (more than 10700)
were in introns and another B200 were in non-translated regions.
These were not analysed further for possible functional signifi-
cance. Of the 181 potential somatic mutations encoding alterations
in protein sequence, many were eventually eliminated from further
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positives, and others were in inherited SNPs or were not confirmed
by PCR. Gene-based analysis of the remaining variants revealed a
total of 10 that are predicted to result in an altered protein
sequence. Of these, two are in genes that have already been shown
to recurrently carry mutations in this tumour type, FLT3 and
NPM1, and eight are therefore newly described and of unknown
function or relevance to the tumourigenic process. On the basis of
studies in additional samples, however, there was no evidence to
suggest that these additional eight genes are recurrently mutated in
AML. Although recurrence would suggest that mutations do
contribute to tumourigenesis, the absence of recurrence does not
necessarily mean that they do not. Although informatics analysis
reduced the number of variants of specific interest to a relative few,
large numbers of additional potentially functional alterations that
could potentially contribute to the cancer repertoire were also
identified, but not deemed accessible for further functional
consideration at this time (and the potential role of insertion/
deletion changes was not considered).
In a subsequent study, Mardis et al (2009) performed Illumina
whole-genome sequencing on a second AML, as well as on a skin
sample derived from the same patient. Of the 52 somatic point
mutations detected, four were recurrent in at least one other
sample. Two of the four alterations were previously unknown in
AML, both with interesting characteristics. In the first instance,
mutations were discovered in the IDH1 gene, at the same position
as in glioblastoma, but with different preferences with respect to
the coding change. These alterations were most prominent in AML
with normal diploid karyotypes. The second alteration, found in an
additional AML sample, is located in a non-genic evolutionarily
conserved region, pointing to the importance of developing a
strategy for informing analysis of non-protein encoding alterations
with potential regulatory functions. Indeed, genome-wide associa-
tion studies also point to inherited non-genic alterations in cancers
(De Gobbi et al, 2006; Steidl et al, 2007; Easton and Eeles, 2008).
Understanding the potential regulatory effects of these alterations
that are currently not understood will be of key importance in
understanding the molecular mechanisms of cancer. In that
regard, progress of the ENCODE project (Birney et al, 2007) will
be beneficial towards providing a platform for providing a context
towards assessing the role of non-genic alterations in cancer
development and progression.
A recent whole-genome analysis of a lobular breast cancer
sample points to informative features of cancer progression
discernible with NextGen sequencing (Shah et al, 2009). In this,
an Illumina sequencing-based approach was used to sequence the
genome of a primary tumour, as well as a metastasis collected from
the same patient 9 years later. The results provided insight into the
evolution of the cancer genome associated with disease progres-
sion. For example, of the 32 somatic alterations detected in
metastasis, only 11 were detected in primary tumour. Moreover,
the digital characteristics of NextGen sequencing revealed
frequency differences among the 11 alterations detectable in
primary tumour, with some being very prevalent in the tumour
and others detectable in as few as 1% of tumour genomes, thereby
reflecting differences in the appearance of changes and/or their
prevalence with specific cell types. As the authors note, the
prevalence of new mutations in metastases could reflect those
associated naturally with tumour progression, as well as those
induced by treatments such as radiation therapy.
A second very notable feature of the study by Shah et al is the
integration of genome and transcriptome analysis. With the
precise view of each facilitated by NextGen sequencing, new
insights into the repertoire of tools accessible to potentially drive
cancer progression are discernible. In this case, several hundred
putative RNA-editing events were observed that would potentially
result in non-synonymous protein changes not coded directly by
the gene. Non-synonymous editing events were confirmed in the
COG3 and SRP9 genes, and it was also noted that the ADAR gene,
encoding a key RNA-editing enzyme, is highly expressed in this
cancer. Together, these results highlight the major theme of the
importance of data integration, and that the quantitative and
digital aspects of NextGen sequencing can together be applied to
an understanding of gene activation/inactivation. This combined
approach thereby provides greater insight into the similarities and
differences of related cancers, and how these features can guide
targeted intervention not only based on specific genetic alterations
but also on all alterations that can contribute to an alteration of
targeted genes and pathways.
These first cancer genome sequences point to the challenge of
functional studies of large numbers of variants of unknown
function. In keeping with that notion, several studies have focused
on sequencing the entire cancer exome (the complete set of exons)
or selected sets of exons in gene families.
THE CURRENT FOCUS ON THE CANCER EXOME
Using the platform of the completed human genome enabled the
cancer research community to pursue the targeted sequencing of
gene families, starting initially with tyrosine kinases (Davies et al,
2002; Bardelli et al, 2003) and progressing recently to almost the
entire human gene content in selected cancers, including breast
and colorectal (Wood et al, 2007), pancreas (Jones et al, 2008) and
glioblastoma (Parsons et al, 2008). These studies have provided
examples of the enhanced value gained through comprehensive
analysis compared with gene-by-gene approaches. The kinome was
an attractive gene family for initial studies, given the successful
introduction of new cancer therapies, such as Gleevec (Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA; Druker,
2008), that target kinases activated in cancers. These studies were
informative in multiple ways. First, the initial report of Bardelli
et al (2003) pointed to the large number of tyrosine kinase genes
mutated in individual colorectal cancers, suggesting that, although
most of these genes carry somatic mutations in a limited number
of tumour samples, together these genes are mutated in a high
proportion of colorectal cancers. Moreover, from these studies,
frequent mutations in particular genes were discovered, including
BRAF in malignant melanoma (Davies et al, 2002) and PIK3CA in
colorectal and other cancers (Samuels et al, 2004), thus identifying
potentially important new targets for therapeutic intervention.
The more recent comprehensive breast and colorectal cancer
studies, comprising the exons of the best-characterised human
genes including those in RefSeq (http://www.ncbi.nlm.nih.gov/
RefSeq/), pointed to the presence of a relatively few genes with
somatic mutations in a high proportion in those cancers, and
a much higher number of genes that are mutated relatively
infrequently. This pattern of mutational frequencies means that
the permutation of mutations in any individual tumour is
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Figure 1 Current targets for genome-wide analysis by high-throughput
sequencing. (A) Whole-genome through shotgun sequencing; (B) regula-
tory protein binding sites such as through Chip-seq; (C) epigenetic
alterations including DNA methylation; (D) regulatory sites including
promoters; (E) exons from selected genes or whole-exome sequencing; (F)
intronic regions within genes; (G) the transcriptome including coding and
non-protein-encoding transcripts (ncRNAs) and microRNAs.
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clearer picture emerges if the mutational patterns are considered
in the context of biological pathways, leading to the identification
of both common and variable features of cancers (Leary et al,
2008). Very informative to this analysis will be the integration of
various data sets towards the definition of the pathways and
networks that drive cancers. Complementary to the study of
genomic changes are the fluid alterations of the coding repertoire,
such as those represented in gene expression levels and the specific
transcript forms that are expressed. As was noted by Shah et al
(2009), integrating these quantitative and qualitative changes in
cancer cells and assessing the changes that actually have functional
consequences become a key issue going forward.
Much of the exome data to date comes from Sanger sequencing
that can best detect those mutations that are clonal within the
tumour, for technical reasons. The use of NextGen technologies for
deeper exome sequencing will now offer the potential to discern
rare events within a tumour or a particular cell type, as the new
technologies are based on amplification of individual molecules.
A most interesting example of this approach was provided by a
study on EGFR-based Gefitinib resistance, which demonstrated
resistance based on mutations that were not clonal, but could be
revealed by application of the 454 Sequencing System (454 Life
Sciences, Branford, CT, USA; Thomas et al, 2005).
THE IMPORTANCE OF INTEGRATED DATA SETS
The whole-cancer exome projects point to the importance of
measuring various forms of perturbational alterations of genes,
including both exonic point mutations and insertion/deletion
events, in assessing the relative potential contribution of any gene
to cancer. In the study by Parsons et al (2008), the two most
commonly altered genes in glioblastoma are predominantly altered
through quite different mechanisms (homozygous deletions for
CDKN2A and point mutations for TP53). Moreover, detailed views
of altered glioblastoma pathways, including TP53, PI3K and RB1,
revealed the presence of point mutations, amplifications and
deletions in each instance. This study also pointed to patterns of
coincidental and exclusive mutations. For example, the newly
identified IDH1 mutation was often coincidental with TP53
mutations (83% of cases compared with 27% in patients with
wild-type IDH1) and negatively correlated with the presence of
PTEN, RB1, EGFR or NF1 mutations (0% of cases compared with
60% in patients with wild-type IDH1), suggesting fundamentally
different cancers at the molecular level. As these patterns are more
extensively studied in the context of tumour progression and
response to therapy, clinical sequencing will become increasingly
useful as a tool for the attending oncologist.
The comprehensive study of glioblastoma also points to the
importance of using different strategies in delineating phenotypic
correlations. This cancer was also selected in The Cancer Genome
Atlas pilot study in which fewer genes were initially sequenced, but
in a deeper sample set (Cancer Genome Atlas Research Network,
2008). The study further showed the importance of integration of
different analytical approaches, in this instance, gene expression
and epigenomic data. This study identified an additional
frequently mutated gene, PIK3R1, as well as a strong association
of the methylation status of the MGMT promoter and frequency of
G–C to A–T transitions within CpG sites compared with non-CpG
dinucleotides. The recognition that the cancer genome is more
than that of the As, Cs, Ts, and Gs through the incorporation of
methylation and additional epigenomic information will be an
increasingly important and commonplace approach while going
forward with NextGen sequencing. Technologies such as Chip-Seq
open new avenues for research, such as in the study of enhancer-
associated regulatory protein binding sites (Visel et al, 2009), as
well as to assess the specific relationships of specific histone
modifications as they relate to features such as transcription factor
binding (Robertson et al, 2008; Gargiulo and Minucci, 2009;
Gargiulo et al, 2009; Neff and Armstrong, 2009).
CANCER GENOME REARRANGEMENTS – AN IMPOR-
TANT COMPONENT OF THE CANCER REPERTOIRE
Rearrangements of the cancer genome, including amplifications/
deletions and chromosomal translocations, represent a biologically
and clinically important, but poorly characterised, class of somatic
variation in cancer. This is especially true in common carcinomas
in which cytogenetic patterns are often very complex. However,
cancer researchers clearly recognise the importance of these
events, especially as they led to the development of two early
successfully targeted cancer therapies, Herceptin (Genentech, Inc,
South San Francisco, CA, USA) (based initially on amplification of
ERBB2 in breast cancer) (Park et al, 2008) and Gleevec (Druker,
2008), based on BCR–ABL translocation in chronic myelogenous
leukaemia.
Advances in sequencing technology currently have a major
impact in illuminating the molecular identity of these events
(Chiang et al, 2009). The very cost-effective deep genome coverage
of NextGen sequencing facilitates a quantitative detection of
regions that are over- or underrepresented, compared with a
reference genome, and that constitute potential regional amplifica-
tions or deletions. In addition, the recent incorporation of paired-
end sequencing in NextGen platforms allows the detection of
insertions/deletions and also translocations based on differential
mapping of the paired-end reads in comparison with the reference
genome.
Initial applications of these approaches have been quite
successful (Bignell et al, 2007; Campbell et al, 2008). For example,
Campbell et al (2008) used Illumina GA technology to attain the
precise sequence of several hundred variants, comprising germline
and somatic intra- and inter-chromosomal rearrangements in two
lung cancer cell lines. The quantity and precision of the data sets
point to the molecular derivation of such rearrangements
including the role of retrotransposons. They also identified
translocation events that result in the generation of novel fusion
genes and transcripts. A deep study of genomes at this level will
now begin to delineate those long-range alterations that are
recurrent and associated with specific clinical features.
THE CANCER TRANSCRIPTOME
Transcriptome analysis has been a major driver in the compre-
hensive molecular characterisation of cancer through expressed
sequence tag sequencing, as well as tag-based approaches
including SAGE. However, even the most imaginative approaches
were of somewhat limited use because of the depth of sequencing
and the information content of sequence tags. NextGen sequencing
incorporating much deeper sequencing now provides glimpses of
the rich information content that can be gleaned from the
transcriptome, including not only alternative splice forms and
non-protein encoding transcripts but also genomic alterations
present in transcripts, such as somatic point mutations and gene
alterations in fusions and truncations (Morin et al, 2008;
Sugarbaker et al, 2008; Maher et al, 2009; Zhao et al, 2009).
For example, Sugarbaker et al (2008) described a deep analysis
of the malignant pleural mesothelioma transcriptome on the basis
of over 260Mb of cDNA sequence generated by 454 Life Sciences
sequencing. The study revealed alternative splice forms, new point
mutations and small deletions resulting in non-synonymous
changes, as well as variants derived from RNA editing. Although
each mesothelioma had a different mutational profile on the basis
of transcripts, several of the newly identified mutations were
observed in multiple samples.
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gleaned from deep-transcriptome sequencing. In these studies
(Maher et al, 2009; Zhao et al, 2009), the transcriptomes of prostate
and breast cancers were analysed for the presence of gene fusion
events that result from chromosomal translocations. In the study
by Zhao et al (2009), the pseudotetraploid breast cancer cell line
HCC1954 was studied in comparison with a non-cancer-derived
cell line from the same patient. Through mapping of B500000
454-derived reads of RefSeq genes, eight novel gene fusion events
were detected that reveal complex molecular events that result in
fusion and truncated proteins, several in genes previously
implicated in cancer. Subsequent verification by PCR and FISH
of genomic DNA confirmed the genomic nature of these events.
The approach of Maher et al (2009) further demonstrated the
use of deep-transcriptome sequencing (in this case, a combination
of 454 Life Sciences long reads and Illumina GA short reads were
used) to identify potential fusions, with initial proof of principle
being to rediscover the BCR–ABL fusion in CML and the recurrent
TMPRSS2-ERG gene fusion in prostate cancer. Several additional
prostate cancer gene fusions were identified, although most are
apparently non-recurrent. Interestingly, the only identified recur-
rent transcript that encoded a fusion protein SLC45A3–ELK4 was
not the result of genomic alteration, but apparently the result of
a read-through transcription. This result further points to the still
new and surprising means in which transcripts are generated to
meet cellular needs, some being hard-wired in the genome, and
others based on mechanisms not fully understood but adding to
the repertoire of genome dynamics.
Finally, the importance of the non-coding transcriptome in
cancer has been a focal point of attention over the past several
years. Even now, new non-coding transcripts with potential
regulatory functions are being discovered through the NextGen
technologies. A recent example is the study by He et al (2008),
in which the human anti-sense transcriptome was characterised
by a tag-based approach on the Illumina GA instrument (Illumina,
Inc, San Diego, CA, USA). Evidence for anti-sense transcripts was
observed for over 6000 human genes pointing towards potential
roles in gene expression, again pointing to the value of deep
sequencing approaches for establishing fundamental components
of the transcriptional apparatus.
IT IS ALL IN THE BIOLOGY
Cancer research has been transformed over the past decade by
comprehensive molecular analysis, resulting in a much greater
understanding of the molecular diversity of cancers, as well as
common features in seemingly very different cancers. Soon, whole-
cancer genome sequencing will become routine, bringing increased
opportunities for invigorating basic discovery and also to make an
impact on patient care. However, substantial challenges remain
before the full potential on the latter can be realised.
As is apparent from recent studies, as well as the sum of research
over the last decade, the numbers of alterations in the cancer
genome, especially in solid cancers, are vast. Moreover, our
knowledge of the repertoire of components that help to orchestrate
cancer transitions has increased in surprising ways, especially in the
context of the diversity and functional roles of non-coding RNAs.
Evident from current results and discussions is the challenge of
understanding the diversity of genomic variants being discovered
and their potential functional roles in cancer (Maher, 2009). Most
analysis still focuses on the exons of cancer genes, and therefore
both exon-based sequencing and transcriptome analysis will attain
increased focus going forward and is likely to represent the
dominant near-term strategy.
Cancer represents a special opportunity not only to study
disease genesis and progression but also to study mechanisms of
cellular regulation, as, for most cancers, both diseased and normal
tissues are accessible from the same patient. We can thus identify
specific genomic alterations in cancer compared with normal cells.
Therefore, as much of cancer change is somatic, the variants that
are causative to cancer will be discernible, although within an
extensive background of variation that is not causative but is
present as a result of the age-related disruption of the genome.
Within this context, we are fortunate to benefit from molecular
organising principles of cancer that emerged even before the era of
genome-wide technologies. Therefore, we have a framework of the
functions that cancer cells must, in common, achieve (Hanahan
and Weinberg, 2000), insights into the pathways and networks
involved as the disease progresses (Jones et al, 2008) and the
diversity of cells that contribute to cancer development, including
to the cancer microenvironment (Weigelt and Bissell, 2008) and
immune system (Dunn et al, 2004). Therefore, although the
number and types of variants are large, and often not understood,
we do possess a strong context within which to consider newly
discovered features of cancer, as we fill-in the overall picture of
cancer. The results of exome analysis to date are somewhat
reminiscent of genome-wide association studies of other complex
diseases in which many genes have a role, and many variants are
likely to be quite rare. However in cancer, rare somatic variants in
diseased tissue can be considered within the framework of known
pathways and networks.
There is strong anticipation that NextGen genomics will lead to
NextGen cancer care. Cancer genome sequencing is rapidly
becoming more cost-effective such that we can envision this
becoming a standard approach in tumour analysis. Indeed, the
cost of the second AML genome was ‘dramatically’ less than
the first, even with greater genome coverage (Mardis et al, 2009).
With ongoing technological advances in DNA sequencing that
will dramatically increase the throughput and reduce the cost,
coupled with enhanced funding for cancer genome sequencing
(Kaiser, 2009), our knowledge of human cancer genomes will
increase dramatically over the next several years. Translating that
sequence information to biological knowledge of cancer represents
the key opportunity and challenge while going forward. Very
important for driving biological knowledge and assessing how
effective current advances are towards patient benefit are the
current efforts to integrate genomic analysis within the clinical
setting. We can certainly expect that a much stronger platform
for informing cancer intervention will emerge on the basis of
these efforts.
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